An Open Label, Single Oral Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-Esreboxetine.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs Esreboxetine (Primary)
- Indications Depressive disorders; Fibromyalgia
- Focus Pharmacokinetics
- Acronyms ADME
- Sponsors Pfizer
- 16 Feb 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 08 Dec 2008 New trial record.